
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is facing challenges with their top-line growth, leading to a downgrade to a Hold rating. With no near-term catalysts in sight and the next potential new products and ANDA approvals not expected until 2027, the company may struggle to meet revenue expectations. While they have a strong presence in the US, the lack of global diversification may also hinder their growth potential.
Bears say
Amphastar Pharma is facing pricing and competitive headwinds in their generics business and their pipeline of new products may not be enough to offset these challenges, making visibility into future top-line and EBITDA growth murky. Previous top-line misses, especially with their flagship product Baqsimi, have led to a decrease in growth expectations and a downgrade to a hold rating. The company's heavy reliance on the success of its pipeline development, as well as significant stock ownership by two directors, presents significant risks to future success.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares